A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/48 (2006.01) A61K 39/00 (2006.01) A61K 39/39 (2006.01) A61P 19/02 (2006.01) A61K 38/11 (2006.01)
Patent
CA 2349748
An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (Kl) by partial sequencing and by enzymatic activity. Further experiments revealed that the excision of SMG (SMGx) from Lewis rats prevents the oral induction of immunological tolerance against native bovine type II collagen (BCII). Thus SMGx rats, when they were given oral BCII and were subsequently immunized with the same antigen, developed collagen induced arthritis (CA), while normal rats given an identical treatment were protected from the disease. When SMGx rats were orally given porcine Kl in conjunction with BCII, the capacity of such animals to develop oral tolerance was fully restored. These results indicate that normal SMG function is required for the induction of oral tolerance and that Kl is involved in mediating this function.
Berczi Istvan
Nagy Eva
Sabbadini Edris
Ridout & Maybee Llp
The University Of Manitoba
LandOfFree
Therapeutic uses of glandular kallikrein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of glandular kallikrein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of glandular kallikrein will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2004777